Core Viewpoint - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers through the inhibition of GSK-3β, with a presentation scheduled at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 [1] Company Overview - Actuate Therapeutics is dedicated to creating therapies for high-impact cancers, with its lead investigational drug, elraglusib, targeting molecular pathways that promote tumor growth and resistance to conventional treatments [4] - Elraglusib functions as a GSK-3β inhibitor and may enhance anti-tumor immunity by regulating immune checkpoints and immune cell function [4] Presentation Details - Dan Schmitt, President & CEO of Actuate, will present at the Oppenheimer conference at 9:20 a.m. ET on February 26, 2026 [1] - A webcast of the presentation will be available, and a replay will be accessible on the company's website for 30 days following the event [2][3] - The management team will also conduct one-on-one meetings with investors during the conference [2]
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference